TickerFacts.

Scilex Holding Co (SCLX): Depreciation & Amortization

Annual figures by period end, from SEC filings.

$4.62M
Year ended 2025-12-31
$8.32M
Trailing 12 months to 2026-06-30
+5.3%
3-year compound annual growth
+4.1%
5-year compound annual growth
2020-12-31: $3.78M2021-12-31: $3.78M2022-12-31: $3.96M2023-12-31: $4.15M2024-12-31: $4.05M2025-12-31: $4.62M$4.62M
2020-12-31 Depreciation & Amortization (USD) 2025-12-31
Period endedDepreciation & AmortizationChange YoYSource filing
2025-12-31$4.62M+14.3%2026-04-10, From 2025-01-01
2024-12-31$4.05M-2.4%2026-04-10, From 2024-01-01
2023-12-31$4.15M+4.7%2025-03-31, From 2023-01-01
2022-12-31$3.96M+4.8%2024-03-12, From 2022-01-01
2021-12-31$3.78M+0.1%2024-03-12, From 2021-01-01
2020-12-31$3.78Mn/a2023-03-07, From 2020-01-01

Depreciation & Amortization at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedDepreciation & AmortizationChange YoY
Scilex Holding Co (SCLX)2025-12-31$4.62M+14.3%
Precision Biosciences Inc (DTIL)2025-12-31$1.47M-56.9%
X4 Pharmaceuticals, Inc (XFOR)2025-12-31$1.28M+60.4%
C4 Therapeutics, Inc. (CCCC)2025-12-31$1.96M+7.8%
Kymera Therapeutics, Inc. (KYMR)2025-12-31$8.31M+12.7%
Sangamo Therapeutics, Inc (SGMOQ)2025-12-31$3.96M-22.4%
Alector, Inc. (ALEC)2025-12-31$5.72M+5.8%
LENZ Therapeutics, Inc. (LENZ)2025-12-31$287.0K+394.8%
Champions Oncology, Inc. (CSBR)2026-04-30$1.38M-16.0%

Compare SCLX, DTIL, XFOR, CCCC side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗